Business
SourcingLink.net Announces Corporate Name Change to Oncology Pharma, Inc.
SourcingLink.net Announces Corporate Name Change to Oncology Pharma, Inc..
About this update from Oncology Pharma Inc.
[{"type":"text","content":"\nNew Name Reflects the Company's Core Business of Oncology Therapeutics\n SAN FRANCISCO, CA, June 17, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – SourcingLink.net, Inc. has announced that it has changed its name to ONCOLOGY PHARMA, INC. (OTCPK: ONPH) (the “Company”). In addition to the new corporate name, the Company has also changed it ticker symbol on the OTC Markets to “ONPH”. Both changes were effective as of June 13, 2019. The new name was chosen to better reflect the Company’s strategic focus on the development, manufacture, and commercialization of oncology treatments and therapeutics. Through its research and development efforts and licensing agreements, and led by a world-class Advisory Board, the Company seeks to be a leader in developing technologies in cancer research, biotechnology, and healthcare. The name change marks a new chapter of the Company’s growth, and completes the process of corporate transition that began when the Company initially decided to move away from its former business. The Company’s mission continues to be the development of oncology treatments for improving both the quantity and quality of life of cancer patients. While there are advances every year in the field of cancer research, there remains a significant unmet medical need in the treatment of cancer. The National Cancer Institute reports that approximately 38.4% of men and women in the U.S. will be diagnosed with cancer at some point during their lifetimes. Further, while the American Cancer Society reports that the cancer death rate in the U.S. for men and women combined has fallen 27% from its peak in 1991, it still estimates that approximately one in four deaths in the United States is due to cancer. To build upon the foundation established by the Company’s licensing arrangement for Tulynode’s patent pending Autologous Immuno-therapy, the Company intends to drive growth by adding additional strategic partnerships and acquisitions. The Company’s new strategy also envisions providing strategic services to pharmaceutical, diagnostic, and academic organizations as they seek to bring new drugs, treatments, and targeted therapies to market. The Company’s new name is intended to highlight the new strategy by providing a corporate identity that accurately represents the C...